Korea University Technology Holdings
3F Techno Complex Building, College of Science & Technology, Korea University, 145 Anam-ro, Seongbuk-gu, Seoul, Seongbuk-gu, 02841, South Korea
Overview
KUH is an accelerator specializing in science and technology start-ups based on university research.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Financial Services
- Funding Platform
Investment portfolio
- CrossPoint Therapeutics
Participated · Seed · Apr 2024
CrossPoint Therapeutics was founded in October 2022 and is developing a proprietary ‘Stealth-Body’ platform that introduces Fc mutations to eliminate effector functions (Fc silencing). The company says its Fc‑silencing eliminates FcγR binding in mice and nonhuman primates while retaining FcRn‑mediated long half‑life. Its pipeline is at lead development stage and includes a safety‑improved antibody‑drug conjugate (ADC), an immune‑modulating ADC (IM‑ADC), and a dual‑target immunotherapy that activates dendritic cells; specific targets have not been disclosed. The platform is positioned to reduce Fc‑mediated off‑target toxicity and to enable modulation of immune or normal cells that were previously difficult to target. CrossPoint licensed the Fc silencing technology from Korea University earlier this year. The founder, Tae‑Erk Kim, has prior leadership experience including roles at KDDF and LeadCompass Investment.
Team
No current team members are available.